Roche Looks Outside Its Labs to Expand Cancer Drug's Potential
- Drugmaker opens door to oncology partnerships on atezolizumab
- Majority of drug combinations focused on internal options
This article is for subscribers only.
Roche Holding AG, the world’s largest producer of cancer drugs, is opening the door to more external partnerships as its latest and most promising tumor-fighting treatment heads for approval this year.
The Basel, Switzerland-based company formed partnerships with Kite Pharma Inc. and Johnson & Johnson in the last week to explore combinations using its experimental drug atezolizumab. The Roche medicine will be studied with Kite’s experimental custom-cell therapy and with Johnson & Johnson’s Darzalex, which is approved in the U.S. for multiple myeloma patients.